Xcout Intel
Coherent Biopharma
Coherent Biopharma is a biotechnology research and pharmaceutical company founded by Robert Huang. Headquartered in Suzhou, China, the firm focuses on targeted protein degradation and advanced drug discovery in oncology and biotherapeutics.
Subscribe to see Coherent Biopharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Coherent Biopharma at a glance
Coherent Biopharma is a biotechnology company headquartered in China. Its most recent funding round, Series B, raised $100M in May 2023. Xcout tracks 3 named people at Coherent Biopharma, including Jun Shao (U.S. GM & COO).
Coherent Biopharma leadership
- Jun ShaoU.S. GM & COO
- Robert HuangFounder, Chair and CEO
- Rong TangSVP
Coherent Biopharma funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $100M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Coherent Biopharma competitors
A few of Coherent Biopharma's closest competitors — see the full list of competitors and alternatives →
Vibrant Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with operations in China. Founded in July 2019, the firm focuses on revolutionizing protein drug discovery and developing next-generation prodrugs with precise targeting.
Chimagen Biosciences is a biopharmaceutical company headquartered in Shanghai, China, founded in July 2016. The company specializes in multi-specific antibody therapeutics and built the proprietary TRIAD platform for engineering.
Constructive Bio is a biotechnology research company headquartered in Cambridge, United Kingdom, that focuses on designing and manufacturing proteins with non-canonical amino acids for new medicines and materials.
Laigo Bio is a biotechnology company that develops targeted protein degradation therapeutics using its proprietary SureTAC platform. The company utilizes bispecific antibodies to direct cell surface targets toward lysosomal degradation, primarily serving the oncology and immunology sectors.
Inventisbio is a biopharmaceutical company that focuses on the discovery and development of innovative drugs for major diseases such as tumors, autoimmune diseases, and metabolic disorders. Utilizing an independent research and development platform, the company creates proprietary drug pipelines targeting oncology drivers, kinases, and autoimmune pathways to serve patients globally.
HitGen Inc. is a biopharmaceutical and contract research company that provides drug discovery services and technologies to the global pharmaceutical and biotechnology industry. It specializes in DNA-encoded library (DEL) technology, fragment-based drug discovery, structure-based drug design, and oligonucleotide-based therapeutics to discover novel small molecules and therapeutics for global clients and internal pipelines.
Get Coherent Biopharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Coherent Biopharma in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access